Interstitial Lung Disease in Japanese Patients with Lung Cancer

2008484 citationsJournal Article

Authors

Shoji Kudoh · Nippon Medical School

Harubumi Kato · Tokyo Medical University Hospital

Yutaka Nishiwaki · National Cancer Center Hospital East

Masahiro Fukuoka · Kindai University

Kouichiro Nakata

Yukito Ichinose · National Hospital Organization Kyushu Cancer Center

Masahiro Tsuboi · Tokyo Medical University Hospital

Abstract

ILD was relatively common in these Japanese patients with NSCLC during therapy with gefitinib or chemotherapy, being higher in the older, smoking patient with preexisting ILD or poor performance status. The risk of developing ILD was higher with gefitinib than chemotherapy, mainly in the first 4 weeks.

Topics & Keywords

Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Lung Cancer Treatments and Mutations Sarcoidosis and Beryllium Toxicity Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: American Journal of Respiratory and Critical Care Medicine

Volume 177, Issue 12, pp. 1348-1357

DOI: 10.1164/rccm.200710-1501oc

Field-Weighted Citation Impact: 18.96